XSHE003042
Market cap278mUSD
Dec 26, Last price
14.26CNY
1D
1.49%
1Q
12.64%
IPO
-45.74%
Name
Shandong Sino-Agri United Biotechnology Co Ltd
Chart & Performance
P/E
—
P/S
1.21
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.99%
Rev. gr., 5y
3.54%
Revenues
1.68b
-13.06%
Net income
0k
-100.00%
CFO
87m
Dividend
Jun 21, 20230.1 CNY/sh
Profile
Shandong Sino-Agri United Biotechnology Co.,Ltd. engages in the development and production of agricultural chemicals and pesticides in China. The company's products include insecticide, such as imidacloprid and acetamiprid; intermediates comprising ethyl n-cyanoethanimideate and n-nitroimino imidazolidine; fungicides, including diethofencarb and myclobutanil1; acaricide, such as fenpyroximate and pyridaben1; and crude drugs and preparation products, and herbicides. It also provides technical consulting services; and exports its products to Southeast Asia, South Asia, the Middle East, Europe, and the United States. The company was founded in 2006 and is based in Jinan, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 1,680,905 -13.06% | 1,933,424 18.97% | 1,625,073 3.63% | ||||||
Cost of revenue | 1,731,927 | 1,709,262 | 1,373,425 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (51,022) | 224,161 | 251,647 | ||||||
NOPBT Margin | 11.59% | 15.49% | |||||||
Operating Taxes | 10,307 | ||||||||
Tax Rate | 4.10% | ||||||||
NOPAT | (51,022) | 224,161 | 241,340 | ||||||
Net income | 73,138 -25.82% | 98,595 -4.76% | |||||||
Dividends | (21,920) | ||||||||
Dividend yield | 0.59% | ||||||||
Proceeds from repurchase of equity | (1) | ||||||||
BB yield | 0.00% | ||||||||
| Debt | |||||||||
Debt current | 425,847 | 326,030 | 276,168 | ||||||
Long-term debt | 379,418 | 249,678 | 248,438 | ||||||
Deferred revenue | 9,101 | 10,113 | 4,301 | ||||||
Other long-term liabilities | 155,524 | 30,558 | |||||||
Net debt | 233,684 | 259,896 | (52,102) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 86,903 | 54,408 | |||||||
CAPEX | |||||||||
Cash from investing activities | (274,005) | ||||||||
Cash from financing activities | 417,256 | 492,246 | |||||||
FCF | (310,753) | (165,921) | (130,711) | ||||||
| Balance | |||||||||
Cash | 571,581 | 315,811 | 575,933 | ||||||
Long term investments | 1 | 2 | 775 | ||||||
Excess cash | 487,536 | 219,140 | 495,455 | ||||||
Stockholders' equity | 618,143 | 870,313 | 785,125 | ||||||
Invested Capital | 1,950,912 | 2,066,688 | 1,645,521 | ||||||
ROIC | 12.08% | 16.42% | |||||||
ROCE | 9.80% | 11.75% | |||||||
| EV | |||||||||
Common stock shares outstanding | 142,571 | 142,480 | 142,480 | ||||||
Price | 18.58 -28.59% | 26.02 30.62% | 19.92 | ||||||
Market cap | 2,648,965 -28.55% | 3,707,330 30.62% | 2,838,202 | ||||||
EV | 2,882,649 | 3,967,226 | 2,786,100 | ||||||
EBITDA | 114,223 | 376,501 | 365,803 | ||||||
EV/EBITDA | 25.24 | 10.54 | 7.62 | ||||||
Interest | 36,624 | 25,435 | 22,782 | ||||||
Interest/NOPBT | 11.35% | 9.05% | |||||||